SBTX.L

SkinBioTherapeutics Plc
SkinBioTherapeutics - Notice of Results
4th December 2024, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 6887O
SkinBioTherapeutics PLC
04 December 2024
 

A blue text on a white background Description automatically generated

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Group")

 

Timing of FY results announcement

4 December 2024 - SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, confirms that, due to the logistics of the auditors sign-off, there will be a short delay in the publication of the FY results. The Directors anticipate that the signing-off of the accounts and in turn, the issue of the FY Results announcement, will happen later today.

-Ends-

 

For more information please contact:

 

SkinBioTherapeutics plc

Stuart J. Ashman, CEO

Manprit Randhawa, CFO

 

 

+44 (0) 191 495 7325

Cavendish Capital Markets Limited
(Nominated Adviser & Broker)

Giles Balleny, Dan Hodkinson (Corporate Finance)

Charlie Combe (Broking)

Dale Bellis, Tamar Cranford-Smith (Sales)

 

+44 (0) 20 7397 8900

Vigo Consulting (financial press)

Rozi Morris

+44 (0) 20 7390 0231

+44 (0) 7740 859 962

Skinbio@vigoconsulting.com

 


 Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements to modulate the immune system by harnessing the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plcand the Group's first in-house product, AxisBiotix-Ps™, is a food supplement to address the symptoms of mild to moderate psoriasis.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.  

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit:www.skinbiotherapeutics.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORDDBDDUSGDGSX]]>
TwitterFacebookLinkedIn